2016 International Congress

Thursday, June 23, 2016

12:00pm-1:30pm

RE-024: A potential phosphopantothenate replacement therapy in 2 patients with pantothenate kinase-associated neurodegeneration (PKAN)

P. Roa, P. Stoeter, E. Perez, M. Santana (Santo Domingo, Dominican Republic)

Clinical trials and therapy in movement disorders  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

RE-024: Mechanism of action and efficacy in non-clinical models

M. Beconi, E. Monteagudo, A. Di Marco, S. Malancona, D. Elbaum, S. Harper (San Diego, CA, USA)

Clinical trials and therapy in movement disorders  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Real world conversion of levodopa to a novel extended release levodopa preparation: Determining predictors and dose ratios

W. Ondo, P. Coss, M. Christie (Houston, TX, USA)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Real-life data on the use of levodopa carbidopa intestinal gel in Parkinson’s disease

J.T. Butler, D. Isaacs, C. Tolleson, R. Pierce, T. Davis (Nashville, TN, USA)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Real-time ultrasound for automated analysis and visualization of neck muscles in cervical dystonia

C. Kobylecki, M.A. Silverdale, R. Cunningham, P. Harding, I.D. Loram (Salford, United Kingdom)

Dystonia  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Recent result of indicative evaluation for deep brain stimulation of Parkinson’s disease patients

H. Saiki, S. Matsumoto (Osaka, Japan)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Reflex saccades changes can estimate long-term symptom progression in DBS STN and MED Parkinson’s disease patients (PD)

S. Szlufik, A. Przybyszewski, J. Dutkiewicz, P. Habela, T. Mandat, D. Koziorowski (Warsaw, Poland)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Regional differences in the results of a phase 2b study of tozadenant in Parkinson’s disease patients with motor fluctuations

C. Kenney, K. Kieburtz, W. Olanow, S. Bandak (San Francisco, CA, USA)

Clinical trials and therapy in movement disorders  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Relationship between balance, trunk impairment and hand function in Parkinson’s disease

B. Donmez Colakoglu, F. Soke, A. Genc, P. Keskinoglu (Izmir, Turkey)

Other  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Relationship of muscular strength with cardiovascular function in Parkinson’s disease

M.A. Alomari, H. Khalil, O.F. Khabour, E. Dersieh, J.A. Bajwa (Irbid, Jordan)

Other  ·  Exhibit Hall located in Hall B, Level 2